Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: Özel Sayı 1

COVID-19 and Sepsis

Pages
3301–3311
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Consideration of severe COVID-19 disease as a sepsis syndrome has relevance and may assist in terms of determining treatments that will modulate the immune response, limit intrinsic damage to tissue and organs, and potentially improve outcome.Key words: COVID-19, sepsis, multiorgan failure, dysregulated immune response, hyperinflammation, cytokine storm

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abstract: The COVID-19 pandemic has created a major alteration in the medical literature including the sepsis discussion.
📊
Key Findings & Data:From the outset of the pandemic, various reports have indicated that although there are some unique features pertinent to COVID-19, many of its acute manifestations are similar to sepsis caused by other pathogens.
💡
Conclusion & Impact:Consideration of severe COVID-19 disease as a sepsis syndrome has relevance and may assist in terms of determining treatments that will modulate the immune response, limit intrinsic damage to tissue and organs, and potentially improve outcome.Key words: COVID-19, sepsis, multiorgan failure, dysregulated immune response, hyperinflammation, cytokine storm
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Abstract: The COVID-19 pandemic has created a major alteration in the medical literature including the sepsis discussion. From the outset of the pandemic, various reports have indicated that although there are some unique features pertinent to COVID-19, many of its acute manifestations are similar to sepsis caused by other pathogens. As a consequence, the old definitions now require consideration of this new etiologic agent, namely SARS-CoV-2. Although the pathogenesis of COVID-19 has not been fully explained, the data obtained so far in hospitalized patients has revealed that serum cytokine and chemokine levels are high in severe COVID-19 patients, similar to those found with sepsis. COVID-19 may involve multiple organ systems. In addition to the lungs, the virus has been isolated from blood, urine, faeces, liver, and gallbladder. Results from autopsy series in COVID-19 patients have demonstrated a wide range of findings, including vascular involvement, congestion, consolidation, and hemorrhage as well as diffuse alveolar damage in lung tissue consistent with acute respiratory distress syndrome (ARDS). The presence of viral cytopathic-like changes, infiltration of inflammatory cells (mononuclear cells and macrophages), and viral particles in histopathological samples are considered a consequence of both direct viral infection and immune hyperactivation. Thromboembolism and hyper-coagulopathy are other components in the pathogenesis of severe COVID-19. Although the pathogenesis of hypercoagulability is not fully understood, it has been pointed out that all three components of Virchow’s triad (endothelial injury, stasis, and hypercoagulable state) play a major role in contributing to clot formation in severe COVID-19 infection. In severe COVID-19 cases, laboratory parameters such as hematological findings, coagulation tests, liver function tests, D-dimer, ferritin, and acute phase reactants such as CRP show marked alterations, which are suggestive of a cytokine storm. Another key element of COVID-19 pathogenesis in severe cases is its similarity or association with hemophagocytic lymphohistiocytosis (HLH). SARS-CoV-2 induced cytokine storm has significant clinical and laboratory findings overlapping with HLH. Viral sepsis has some similarities but also some differences when compared to bacterial sepsis. In bacterial sepsis, systemic inflammation affecting multiple organs is more dominant than in COVID-19 sepsis. While bacterial sepsis causes an early and sudden onset clinical deterioration, viral diseases may exhibit a relatively late onset and chronic course. Consideration of severe COVID-19 disease as a sepsis syndrome has relevance and may assist in terms of determining treatments that will modulate the immune response, limit intrinsic damage to tissue and organs, and potentially improve outcome.Key words: COVID-19, sepsis, multiorgan failure, dysregulated immune response, hyperinflammation, cytokine storm

🔖

Cite This Article

KAYAASLAN, B., TUFAN, Z. K., MER, M. (2022). COVID-19 and Sepsis. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: Özel Sayı 1, 3301–3311. https://ajindex.com/articles/609351

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Genga KR, Russell JA. Update of Sepsis in the Intensive Care Unit. Journal of Innate Immunity 2017
  2. 9(5): 441-455. doi: 10.1159/000477419 2. Perner A, Gordon AC, De Backer D, Dimopoulos G, Russell JA, et al. Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Med. 2016 Dec
  3. 42(12):1958-1969. doi: 10.1007/s00134-016-4577-z. 3. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine 1992
  4. 20(6): 864-874. 4. Rello J, Valenzuela-Sánchez F, Ruiz-Rodriguez M, Moyano S. Sepsis: A Review of Advances in Management. Advances in Therapy 2017
  5. 34(11): 2393-2411. doi: 10.1007/s12325-017- 0622-8 5. Faix JD. Biomarkers of sepsis. Critical Reviews in Clinical Laboratory Sciences 2013
  6. 50(1): 23-36. doi: 10.3109/10408363.2013.764490 6. Huang C, Wang Y, Li X, Huang C, Wang Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020
  7. 395(10223): 497-506. doi: 10.1016/S0140- 6736(20)30183-5 7. Liu J, Li S, Liu J, Liang B, Wang X et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020
  8. 102763. doi: 10.1016/j. ebiom.2020.102763 8. Satış H, Özger HS, Aysert Yıldız P, Hızel K, Gulbahar Ö et al. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19. Cytokine 2021
  9. 155302. doi: 10.1016/j.cyto.2020.155302 9. Bellinvia S, Edwards CJ, Schisano M, Banfi P, Fallico M, Murabito P. The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm? Inflammation Research 2020
  10. 69(8): 757-763. doi: 10.1007/s00011-020-01366-6 10. Li H, Liu L, Zhang D, Xu J, Dai H et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 2020
  11. 395(10235): 1517-1520. doi: 10.1016/S0140-6736(20)30920-X 11. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Journal of American Medical Association 2016
  12. 315(8): 801-810. doi: 10.1001/ jama.2016.0287 12. Liu V, Escobar GJ, Greene JD, Soule J, Whippy A et al. Hospital deaths in patients with sepsis from 2 independent cohorts. Journal of American Medical Association 2014
  13. 312(1): 90-2. doi: 10.1001/jama.2014.5804 13. Rho